ATRIUM HEALTH CABARRUS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $45M
- Transactions
- 4,415
- Companies
- 40
- Average per transaction
- $10,185
Who reported the payments
| Janssen Research & Development, LLC | $4,547,188 |
| Amgen | $4,064,485 |
| E.r. Squibb & Sons, L.L.C. | $3,114,263 |
| Vertex | $2,270,279 |
| AstraZeneca | $2,147,788 |
| Genentech, Inc. | $2,061,837 |
| Astrazeneca UK Limited | $2,055,308 |
| Eli Lilly | $1,653,287 |
| AbbVie | $1,597,229 |
| Seagen Inc. | $1,485,359 |
| Abbott | $1,419,589 |
| TG Therapeutics, Inc. | $1,258,637 |
| Merck | $1,223,488 |
| Novartis | $1,197,518 |
| Bristol Myers Squibb | $1,135,055 |
| Edwards Lifesciences | $856,290 |
| Boston Scientific | $742,951 |
| Regeneron | $662,666 |
| Gilead | $633,975 |
| Pfizer | $633,031 |
| Takeda Pharmaceuticals U.S.A., Inc. | $584,126 |
| Smith+Nephew | $553,126 |
| Epizyme, Inc. | $540,912 |
| Kls-martin L.p. | $532,936 |
| Daiichi Sankyo Inc. | $462,236 |
| Intercept Pharmaceuticals, Inc. | $445,687 |
| F. Hoffmann-la Roche AG | $427,063 |
| Heartflow, Inc. | $392,528 |
| Exelixis Inc. | $354,342 |
| Pharmacyclics LLC, An Abbvie Company | $329,449 |
| Dynavax Technologies Corporation | $320,498 |
| Janssen Scientific Affairs, LLC | $310,766 |
| Ethicon Endo-surgery Inc. | $305,736 |
| Karyopharm Therapeutics Inc. | $300,205 |
| National Marrow Donor Program | $267,830 |
| Roche Products Limited | $223,291 |
| Incyte Corporation | $216,384 |
| Roche Diagnostics Operations, Inc. | $210,430 |
| Medical Device Business Services, Inc. | $201,830 |
| Jazz Pharmaceuticals Inc. | $157,732 |